ACORDA THERAPEUTICS INC. overview

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2023. “INBRIJA’s growth in the first half of 2023 improved significantly versus the first half of 2022, including a 42% increase in new prescription request forms, or PRFs. New PRFs are a leading indicator of future revenue growth, which we expect will accelerate going forward. We are seeing the impact of the new sales and marketing programs we...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign. The campaign, “For the Fighters, ” is based on direct feedback from people with Parkinson’s (PwPs). It honors the fighting spirit of the Parkinson’s community, encouraging PwPs to step up their fight by considering whether an on-demand treatment for OFF periods, such as INBRIJA, is right for them. The campaign can be viewed at...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results on Tuesday, August 8 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/268055678 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Tom Burns, Chief Financial Officer at XOMA Corporation, has been elected to its Board of Directors by the stockholders at the Company’s Annual Meeting. Jeff Randall, who had served on Acorda’s Board since 2006 and was Chair of the Audit Committee, has rotated off the Board. “Tom is a highly experienced, savvy financial executive, and we are delighted that he has joined our Board. His decades-long track record of achievement will...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-adjusted basis at the market open on June 5, 2023. The reverse stock split was effected to enable the Company to regain compliance with the $1.00 per share minimum closing...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 4:01 p.m. Eastern Time, on June 2, 2023. The Company’s common stock will begin trading on a post-split basis at the market open on June 5, 2023. The reverse stock split is being effected to regain compliance with the $1.00 per share minimum closing price required to...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Wednesday, June 7 at 1:00pm ET, 10:00am PT. Dr. Cohen will provide an update of the Company’s recent activity and review its Q1 2023 financial and business performance. Participants will be able to submit questions to Dr. Cohen, which he will address live. Video Q&A Registration/Participation Instructions To register for the video event: Click the link below from a laptop or mobile device....